The Cooper Cancer Institute and Cooper Bone and Joint Institute have partnered to open the Orthopaedic Oncology Center, a multidisciplinary program dedicated to treating metastatic bone tumors, sarcomas and benign tumors of the bone and soft tissue. Under the direction of Richard D. Lackman, MD, FACS, who joined Cooper in July, this comprehensive program is the first of its kind in South Jersey.
Dr. Lackman, a nationally recognized expert and the first fellowship-trained orthopaedic oncologist in the Philadelphia region, joined Cooper after serving as Associate Director, Patient and Family Services at the Abramson Cancer Center and Director, Sarcoma Center of Excellence, both at the University of Pennsylvania.
Benign or malignant tumors can develop in the large or small bones of the limbs, spine and pelvis and in muscles, fat, joints, nerves or blood vessels. Primary malignant tumors of bone (bone sarcomas) affect approximately 3,000 people in the United States annually, while primary malignant tumors of soft tissue (soft tissue sarcomas) affect about 10,000 people.
“Because of their rarity and complexity, musculoskeletal tumors pose difficult challenges when it comes to diagnoses and treatment. At Cooper, we take a multidisciplinary approach to cancer care that puts an entire team of experts behind each patient, every step of the way,” says Dr. Lackman. “Beginning with an accurate diagnosis, we create an individualized treatment plan for each patient using the most advanced options available in a compassionate and caring environment.”
Cooper’s multidisciplinary team includes members of radiation oncology and hematology/medical oncology. The team collaborates daily to provide patients with access to cutting-edge diagnostic and treatment technologies, innovative limb- sparing and reconstructive surgery, the latest clinical trials, and a full range of supportive care services.
The Cooper Orthopaedic Oncology Center is located at Three Cooper Plaza, Suite 400, Camden, New Jersey.